Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


GE healthcare Vice president becomes Chairman of LUX biotechnology ltd


Edinburgh, UK - LUX Biotechnology Ltd (LUX) announced today that Dr Jim Brown, the exiting Senior Executive of GE Healthcare is joining the Company as Chairman of the board of directors.

LUX is a specialist developer of luminescent and fluorescent technologies. LUX’s product range includes reagents, bioassays, devices, and certified reference materials. The Company’s strategy is to combine its proprietary bioassay technology and light reporter systems for a variety of applications including drug discovery, research tools, toxicity testing, and diagnostics. As LUX moves toward expanding its operations Dr Ian Sword, former Chairman of the Board, is leaving the company in mutual agreement.

Dr Ian Sword said: “LUX biotech has a strong range of technologies and they have a bright future ahead of them. I am delighted that Dr Brown is joining the team. His strong industry experience will help LUX through its next stage of growth by successfully placing its technologies in the market.”

Dr Brown’s career spans 35 years of prolific research and senior executive positions in Pharmaceutical and Biotech Industry – Inveresk Research, Bioreliance, Mangenta Biotech, Amersham and finally as president of GE Healthcare. He is also a founder member of both BIO in the US and UK Bioindustry Association. Dr Brown is retiring from his position at GE Healthcare but will continue working with a number of companies at senior level.

Dr Brown stated:” I am proud to be invited to become the new Chairman of LUX Biotechnology. At this point in my life, I wish to use my experience to assist exciting young companies, such as LUX to establish their technologies in the world market. The company has excellent technology which the global Bioscience and Health Science industries need. The rationale for my appointment to the Board is that the company believes that I can assist in taking LUX to the next steps by securing international recognition and acceptance of its developments. I am excited to be involved in establishing LUX in the global market and to be part of the next phase of its growth. All the elements for success already exist i.e. The Right Products, A Significant Market Which Will Deliver Double Digit Growth For Many Years To Come and most important of all, A World Class Senior Management Team And Board.”

Commenting on Dr Jim Brown’s appointment Dr Artin Moussavi, CEO OF LUX said: “Jim joins us at a very exciting time. Our foremost goal was to select an experienced Chairman who could support LUX’s evolution into a global technology Company. With Jim, we have succeeded in attracting someone who has a proven track record in developing such a company.

Commenting on Dr Sword’s retirement from LUX Dr Moussavi said: “We are very grateful to Ian who oversaw the development of LUX over a period of two years from early foundations and first round financing. Ian has done a tremendous job. All of us at LUX wish Ian every success in his next endeavour”.

--ends--

Word count: 500

Additional Information

LUX biotechnology ltd (LUX)
LUX (www.luxbiotech.com) is based in Edinburgh, Scotland. The company was established in 2001 and is wholly privately owned. The Company’s product range includes reagents, bioassays, devices, and certified reference materials. In 2004 LUX launched its first products into the international market. Glowell™ - a range of certified reference standards provide calibration and validation of a wide range of light measuring systems while simultaneously acting as standards for experimental data. LUX bioassays (toxicity assay LuTox™; antifungal drug discovery assay - LuSight™) emit light under test conditions, enabling high throughput and real-time measurement of samples. They are compatible with most analytical equipment and provide cost effective high throughput testing for pharmaceutical, environmental, cosmetic, and food sample testing. Scientists at LUX are the first to develop screens using fungi that express gen


Publisher Contact Information:

LUX Biotechnology Ltd.
+44 131 662 3350
vm@luxbiotech.com

Company profile of LUX Innovate Ltd.
Past press releases of LUX Innovate Ltd..

Data


26,129
Tech investments
From our Online Data Service
16,883
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 13N/AEnergy related
Sep 13€12.6MConsumer electronics
Sep 12€39.0MBiopharmaceuticals
Sep 12N/AKnowledge management
Sep 12€2.3MInternet commerce
Sep 12€2.1MInternet services
Sep 12€4.0MMedical devices

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.